MONMOUTH JUNCTION, NJ -- (Marketwired) -- 12/16/13 -- CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
DIVI, or the German Interdisciplinary Coalition for Intensive Care and Emergency Medicine, is one of the premier German medical societies dedicated to improving outcomes in patients in the intensive care unit and emergency room. Its members primarily consist of critical care and emergency medicine physicians, nurses, and other healthcare providers of all levels of experience throughout the region. This month, the DIVI 2013 Congress attracted approximately 3,000 attendees from the region.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, stated, "The DIVI Annual Congress is a key event for us because it gives invaluable access to thousands of critical care physicians and nurses, both senior and junior, in our core direct sales markets of Germany, Austria, and Switzerland. This is a perfect fit as we continue to drive awareness and usage of CytoSorb® amongst these providers deep within each critical care department. Interestingly, the conference is conducted exclusively in German, making it easy and comfortable for all native German-speaking attendees to fully understand the scientific content. Also of note, walking through the exhibition hall, CytoSorbents continues to stand out as one of the only true innovations in the treatment of patients in the ICU."
Dr. Chan continued, "This year, in addition to exhibiting, we had a very ambitious agenda. Prior to the start of the Congress, we hosted our first ever CytoSorb® user's meeting, where treatment pioneers from all over Germany and Austria gathered to share their clinical experiences using CytoSorb® in fifteen presentations throughout the day and during dinner at night. The presented case reports and case series encompassed hundreds of treatments ranging from the treatment of severe sepsis and septic shock, rhabdomyolysis, liver disease, necrotizing fasciitis, and others, to the use of CytoSorb® both intra-operatively and post-operatively in cardiac surgery, and with ECMO (extracorporeal membrane oxygenation) to stabilize a patient in air transport."
"There was an energy and excitement level amongst the user's group that is difficult to explain," Dr. Christian Steiner, Vice President of Sales and Marketing, remarked. "A repeated message throughout the meeting was that the doctors could see the therapy 'turning the patient around' with an immediate positive effect on patient stability in many cases, as seen by a reduction in vasopressor or oxygen usage for example. This could often be matched with a significant reduction in cytokines and other inflammatory markers. To hear this, and to see the data that CytoSorb® was not just a 'black box', but was working to help physicians regain control of their patients across a wide range of applications, was very exciting. In addition, we continue to receive common feedback that CytoSorb® is easy and safe to use, without complications. Most of the presenters plan to submit their data for publication in the near future, and because of this, the public availability of these presentations is limited."
In addition to the user's meeting, CytoSorbents also sponsored a 90 minute symposium entitled, "SIRS and Sepsis -- A New Therapy Approach with CytoSorb®". The event featured presentations from:
In addition, Prof. Dr. Frank Brunkhorst from the University of Jena Hospital, announced the initial development of the SepNet CytoSorb® Registry. The University of Jena is one of the leading institutions in sepsis and critical care research in the world, and the home of the German Sepsis Society and the Sepsis Trials Network (SepNet) -- a government funded consortium of physicians and hospitals throughout Germany that conduct clinical trials in sepsis. This registry will become a central repository of clinical data from usage of CytoSorb® all over the world, in many different applications, not just sepsis.
Dr. Chan commented, "Given the early morning start and specific focus of the symposium on CytoSorb®, we expected approximately 50-75 people to attend, but were pleasantly surprised to have nearly 120 people attending the session. The presentations were excellent, covering our two leading indications for CytoSorb® -- sepsis and cardiac surgery. The feedback mirrored our exhibit booth traffic, where the level of interest in CytoSorb® from both physicians and nurses was fantastic."
Photos from the user's meeting, company sponsored symposium, and conference can be viewed starting later today on our Twitter feed (https://twitter.com/CytoSorbents) and on our Facebook page at: https://www.facebook.com/#!/cytosorbents
The DIVI (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin) Society was founded in 1977 to foster the cooperation and exchange of knowledge and information between physicians, nurses and other healthcare professionals who specialize in intensive care and emergency medicine. The goal of this premier organization is to foster a collaborative environment where advances in medicine and patient care can be shared, to benefit the welfare of patients. http://www.divi2013.de/index.php?id=37
About CytoSorbents Corporation
CytoSorbents is a critical care focused therapeutic device company using blood purification to modulate inflammation - with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the mortality is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on April 3, 2013, which is available at http://www.sec.gov.